Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT

Core Viewpoint - Altimmune faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint analysis [2][3]. Group 1: Trial Results - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, revealing a failure to achieve statistical significance in fibrosis reduction [2]. - The trial showed a positive trend in fibrosis improvement; however, this was overshadowed by a higher-than-expected placebo response [2]. Group 2: Stock Market Reaction - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [3]. Group 3: Legal Proceedings - A court-appointed lead plaintiff has been established, representing the investor with the largest financial interest in the class action lawsuit against Altimmune [4]. - Members of the putative class have the option to serve as lead plaintiff or remain absent, with their ability to share in any recovery unaffected by this decision [4]. Group 4: Whistleblower Information - Faruqi & Faruqi, LLP is encouraging individuals with information regarding Altimmune's conduct, including whistleblowers and former employees, to come forward [5].